GSK, Angiochem to develop drugs for lysosomal disease symptoms

02/27/2012 | Reuters

GlaxoSmithKline and Angiochem agreed to develop treatments intended to relieve neurological symptoms related to lysosomal storage diseases. Angiochem could get more than $300 million, including as much as $31.5 million upfront, plus sales royalties.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA